Medpace reports Q4 revenue of USD 708.5 million, up 32%

Reuters

Feb 10

Medpace reports Q4 revenue of USD 708.5 million, up 32%

Medpace Holdings Inc. reported fourth quarter (Q4) 2025 revenue of USD 708.5 million, an increase of 32.0%. Net income attributable to shareholders for Q4 2025 was USD 135.1 million, with diluted earnings per share at USD 4.67. The net income margin for the period was 19.1%. EBITDA reached USD 160.2 million for Q4 2025, representing an increase of 20.0% and an EBITDA margin of 22.6%. Net new business awards in Q4 2025 totaled USD 736.6 million, up 39.1%, resulting in a net book-to-bill ratio of 1.04x. Backlog as of December 31, 2025 stood at USD 3.03 billion, an increase of 4.3%. Medpace highlighted that the backlog conversion rate for the quarter was 23.6%. The company uses EBITDA and EBITDA margin as key metrics for evaluating operating performance and incentive planning.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medpace Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260209247649) on February 09, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2610669986"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2610669986\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2610669986?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-10 05:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610669986","market":"us","top_or_hot":-1,"title":"Medpace reports Q4 revenue of USD 708.5 million, up 32%","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Medpace reports Q4 revenue of USD 708.5 million, up 32%\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/MEDP\">Medpace Holdings Inc.</a> reported fourth quarter (Q4) 2025 revenue of USD 708.5 million, an increase of 32.0%. Net income attributable to shareholders for Q4 2025 was USD 135.1 million, with diluted earnings per share at USD 4.67. The net income margin for the period was 19.1%. EBITDA reached USD 160.2 million for Q4 2025, representing an increase of 20.0% and an EBITDA margin of 22.6%. Net new business awards in Q4 2025 totaled USD 736.6 million, up 39.1%, resulting in a net book-to-bill ratio of 1.04x. Backlog as of December 31, 2025 stood at USD 3.03 billion, an increase of 4.3%. Medpace highlighted that the backlog conversion rate for the quarter was 23.6%. The company uses EBITDA and EBITDA margin as key metrics for evaluating operating performance and incentive planning.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medpace Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260209247649) on February 09, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Medpace reports Q4 revenue of USD 708.5 million, up 32%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMedpace reports Q4 revenue of USD 708.5 million, up 32%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-10 05:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Medpace reports Q4 revenue of USD 708.5 million, up 32%\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/MEDP\">Medpace Holdings Inc.</a> reported fourth quarter (Q4) 2025 revenue of USD 708.5 million, an increase of 32.0%. Net income attributable to shareholders for Q4 2025 was USD 135.1 million, with diluted earnings per share at USD 4.67. The net income margin for the period was 19.1%. EBITDA reached USD 160.2 million for Q4 2025, representing an increase of 20.0% and an EBITDA margin of 22.6%. Net new business awards in Q4 2025 totaled USD 736.6 million, up 39.1%, resulting in a net book-to-bill ratio of 1.04x. Backlog as of December 31, 2025 stood at USD 3.03 billion, an increase of 4.3%. Medpace highlighted that the backlog conversion rate for the quarter was 23.6%. The company uses EBITDA and EBITDA margin as key metrics for evaluating operating performance and incentive planning.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medpace Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260209247649) on February 09, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2065169927.USD","symbol_name":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260209:nNDLRpP5R:1","article_id":"2610669986","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2610669986","pubTimestamp":1770671751,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Medpace Holdings Inc. reported fourth quarter  2025 revenue of USD 708.5 million, an increase of 32.0%. Net income attributable to shareholders for Q4 2025 was USD 135.1 million, with diluted earnings per share at USD 4.67. The net income margin for the period was 19.1%. EBITDA reached USD 160.2 million for Q4 2025, representing an increase of 20.0% and an EBITDA margin of 22.6%. Net new business awards in Q4 2025 totaled USD 736.6 million, up 39.1%, resulting in a net book-to-bill ratio of 1.04x. Backlog as of December 31, 2025 stood at USD 3.03 billion, an increase of 4.3%. Medpace highlighted that the backlog conversion rate for the quarter was 23.6%. The company uses EBITDA and EBITDA margin as key metrics for evaluating operating performance and incentive planning.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purp","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","BK4121":"生命科学工具和服务","LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC","MEDP":"Medpace Holdings Inc.","BK4585":"ETF&股票定投概念","BK4588":"碎股","LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC"},"translate_title":"Medpace报告第四季度收入为7.085亿美元，增长32%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MEDP":0.9},"content_text":"Medpace reports Q4 revenue of USD 708.5 million, up 32%\n    \n\nMedpace Holdings Inc. reported fourth quarter (Q4) 2025 revenue of USD 708.5 million, an increase of 32.0%. Net income attributable to shareholders for Q4 2025 was USD 135.1 million, with diluted earnings per share at USD 4.67. The net income margin for the period was 19.1%. EBITDA reached USD 160.2 million for Q4 2025, representing an increase of 20.0% and an EBITDA margin of 22.6%. Net new business awards in Q4 2025 totaled USD 736.6 million, up 39.1%, resulting in a net book-to-bill ratio of 1.04x. Backlog as of December 31, 2025 stood at USD 3.03 billion, an increase of 4.3%. Medpace highlighted that the backlog conversion rate for the quarter was 23.6%. The company uses EBITDA and EBITDA margin as key metrics for evaluating operating performance and incentive planning.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medpace Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260209247649) on February 09, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}